Importance of PSA velocity and PSA density in the predicion of prostate cancer in turp or open prostatectomy specimen of patients with previous negative prostate biopsy;Importancia de la velocidad y la densidad de PSA en la predicción de cáncer de próstata en la pieza de RTU o adenomectomía de pacientes con biopsia prostática previa negativa

Actas Urologicas Espanolas

Volumn 32, Issue 8, 2008, Pages 779-786

  Rodriquez Alonso A ^a   Gonzalez Blanco A ^a   Barbagelata Lopez A ^a   Pita Frenandez S ^b   Suarez Pascual G ^a   Bonelli Martin C ^a   Cuerpo Perez M A ^a  

^a Servicio de Medicina Interna   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Biopsy; Diagnosis; Prostate specific antigen; Prostatic neoplasms; Transurethral resection of prostate

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BIOPSY; BLOOD; HUMAN; LABORATORY DIAGNOSIS; MALE; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE; PROSTATE TUMOR; PROSTATECTOMY; RETROSPECTIVE STUDY; TRANSURETHRAL RESECTION;

AGED; AGED, 80 AND OVER; BIOPSY; FALSE NEGATIVE REACTIONS; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 58149401855     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-4806(08)73935-4     Document Type: Article

References (21)

1. Zigeuner R, Schips L, Lipsky K, Auprich M, Salfellner M, Rehak P, et al. Detection of prostate cancer by TURP of open surgery in patients with previously negative transrectal prostate biopsies. Urology. 2003;62(5): 883-887.
2. Puppo P, Introini C, Calvi P, Naselli A. Role of transurethral resection of the prostate and biopsy of the peripheral zone in the same session after repeated negative biopsies in the diagnosis of prostate cancer. Eur Urol. 2006;49(5):873-878.
3. Borboroglu PG, Comer SW, Riffenburgh RH, Amling CL. Extensive repeat transrectal ultrasound guided prostate biopsy in patients with previous benign sextant biopsies. J Urol. 2000;163(1):158-162.
4. Bratt O. The difficult case in prostate cancer diagnosis when is a "Diagnostic TURP" indicated?. Eur Urol. 2006;49(5):769-771.
5. Rodríguez Alonso A, González Blanco A, Pita Fernández S, Suárez Pascual G, Bonelli Martín C, Lorenzo Franco J, et al. Prostate cancer diagnosis using 24 cores extended biopsy. Actas Urol Esp. 2005;29(10): 934-942.
6. Yu X, Han M, Loeb S, Gashti S, Yeh JT, Roehl KA, Catalona WJ. Comparison of methods for calculating prostate specific antigen velocity. J Urol. 2006;176(6 Pt 1):2427-2431.
7. Puppo P. Repeated negative prostate biopsies with persistently elevated or rising PSA: A modern urologic dilemma. Eur Urol. 2007;52(3):639-641.
8. Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F. Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol. 2007;52(5):1309-1322.
9. Fleshner N, Klotz L. Role of "saturation biopsy" in the detection of prostate cancer among difficult diagnostic cases. Urology. 2002;60(1):93-97.
10. Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: When should we stop?. J Urol. 2001;166(5):1679-1683.
11. Van Renterghem K, Van Koeveringe G, Achten R, Van Kerrebroeck P. Clinical relevance of transurethral resection of the prostate in "asymptomatic" patients with an elevated prostate-specific antigen level. Eur Urol. 2007;52(3):819-826.
12. Steuber T, Karakiewicz PI, Augustin H, Erbersdobler A, Lange I, Haese A, et al. Transition zone cancers undermine the predictive accuracy of Partin table stage predictions. J Urol. 2005;173(3):737-741.
13. Djavan B, Remzi M, Zlotta AR, Ravery V, Hammerer P, Reissigl A, et al. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: Results of the Prospective Multicenter European Trial. Urology. 2002;60(4 Suppl 1):4-9.
14. Ornstein DK, Rao GS, Smith DS, Andriole GL. The impact of systematic prostate biopsy on prostate cancer incidence in men with symptomatic benign prostatic hyperplasia undergoing transurethral resection of the prostate. J Urol. 1997;157(3):880-884.
15. Pelzer AE, Bektic J, Berger AP, Halpern EJ, Koppelstätter F, Klauser A, et al. Are transition zone biopsies still necessary to improve prostate cancer detection? Results from the Tyrol Screening project. Eur Urol. 2005;48(6):916-921.
16. Kirkham APS, Emberton M, Allen C. How good is MRI in detecting and characterising cancer within the prostate?. Eur Urol. 2006;50(6):1163-1175.
17. Amsellem-Ouazana D, Younes P, Conquy S, Peyromaure M, Flam T, Debré B, et al. Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. Eur Urol. 2005;47(5):582-586.
18. Niesel T, Breul J, Hartung R. Diagnostic value of additional systematic prostate biopsies in patients undergoing transurethral resection of the prostate. Urology. 1997;49(6): 869-874.
19. Djavan B, Remzi M, Marberger M. When to biopsy and when to stop biopsying. Urol Clin North Am. 2003;30(2):253-262.
20. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53(1):68-80.
21. Wendt-Nordahl G, Häcker A, Reich O, Djavan B, Alken P, Michel MS. The Vista system: a new bipolar resection device for endourological procedures: comparison with conventional resectoscope. Eur Urol. 2004;46(5):586-590.